Cullinan Therapeutics, Inc., in collaboration with Taiho Oncology and Taiho Pharmaceutical, announced positive Phase 3 REZILIENT3 trial results for zipalertinib plus chemotherapy versus chemotherapy alone in first-line EGFR exon 20 insertion mutation-positive non-small cell lung cancer. The combination therapy demonstrated a statistically significant progression-free survival benefit of 14.5 months compared to 8.5 months (hazard ratio 0.50; P=0.00015). Objective response rates were higher for the combination arm at 65.0% versus 40.3%. The filing does not contain a stock split or dividend announcement. Cullinan Therapeutics operates in the biopharmaceutical industry, developing T cell engagers for autoimmune diseases and cancer.
